Perception of quality of life of persons with HIV/AIDS and maintenance of nutritional parameters while on protease inhibitors

AIDS Patient Care and STDs

Volumn 13, Issue 7, 1999, Pages 427-433

  Echeverria, Pamela S ^a   Jonnalagadda, Satya S ^a   Hopkins, Barbara L ^a   Rosenbloom, Christine A ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUTRITIONAL STATUS; QUALITY OF LIFE; VIRUS LOAD;

EID: 0032855427     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.1999.13.427     Document Type: Article

References (31)

1. Phillips KD. Protease Inhibitors: A new weapon and new strategy against HIV. J Assoc Nurses AIDS Care 1996;5:57-71.
2. LeLacheur SF. Applying new therapies for HIV diseases. J Am Acad Physician Assist 1997;10:51-67.
3. McDonald C, Kuritzkes D. Human immunodeficiency virus 1 protease inhibitors. Arch Intern Med 1997;157:951-959.
4. Center for Disease Control and Prevention HIV/AIDS Surveillance Report. U.S. Dept. of Health and Human Services 1997;9(No.1):1-37.
5. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS defining events and hospitalizations in 10 french AIDS reference centers. AIDS 1997;11:101-105.
6. Flexner C. HIV protease inhibitors. N Engl J Med 1998;38:1281-1291.
7. Sowell R. Advances in the treatment of HIV: Hope and challenge. J Assoc Nurses AIDS Care 1997; 8:21-29.
8. Sowell R, Phillips K, Grier J. Restructuring life to face the future: the perspective of men after a positive response to protease inhibitor therapy. AIDS Patient Care STDs 1998;12:33-42.
9. Bradford D. Update on issues for HIV management. Aust Fam Physician 1997;26:812-817.
10. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
11. Hyman C, Kaufman S. Nutritional impact of acquired immune deficiency syndrome: A unique counseling opportunity. J Am Diet Assoc 1989;89:520-524.
12. Chlebowski R, Grosvenor M, Lillington L, Sayre J, Beall G. Dietary intake and counseling, weight maintenance, and the course of HIV infection. J Am Diet Assoc 1995;95:428-435.
13. Lenderking W, Testa M, Katzenstein D, Hammer S. Measuring quality of life in early HIV disease: The modular approach. Qual Life Res 1997;6:515-530.
14. Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Muller M. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:239-246.
15. Young J. HIV and medical nutrition therapy. J Am Diet Assoc 1997;10:S161-S166.
16. Weinroth S, Parenti D, Simon G. Wasting syndrome in AIDS: Pathophysiologic mechanisms and therapeutic approaches. Infect Dis 1995;4:76-94.
17. Chan R, Gorga D, Ilaria G, Damson L, Jacobs J. Quality of life issues in individuals with HIV disease: An occupational therapy perspective. AIDS Patient Care STDs 1996;10:236-239.
18. Lepl'ege A, Rude N, Ecosse E, Ceinos R, Dohin E, Pouchot J. Measuring quality of life from the point of view of HIV-positive subjects: The HIV-Q131. Qual Life Res 1997;6:585-594.
19. Holmes WC, Shea JA. Performance of a new HIV/AIDS-targeted quality of life (HAT-QOL) instrument in asymptomatic seropositive individuals. Qual Life Res 1997;6:561-571.
20. Hickey A, Bury G, O'Boyle C, Bradley F, O'Kelly F, Shannon W. A new form individual quality of life measure (SEIQOL-DW): Application in a cohort of individuals with HIV/AIDS. Br Med J 1996;313:29-33.
21. Peterman A, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res 1997;6: 572-584.
22. Hogg R, Rhone S, Yip B. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998;12: 279-284.
23. Hirschel B. Progress and problems in the fight against AIDS. N Engl J Med 1998;338:906-908.
24. Gallet B, Pulk M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HTV protease inhibitors (correspondence). Lancet 1998;351: 1958-1959.
25. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
26. Behren G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998; 351:1958.
27. Vittecoq D, Esccaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998;351:1959.
28. Laurence J. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998;351:1960.
29. Kotler D, Hellerstein M, Gardner-Fields C, Smith J. Nutritional aspects of HIV/AIDS. AIDS/HIV Treatment Directory 1995;7:7-11.
30. Grassi L, Sighinolfi L. Psychosocial correlates of quality of life in patients with HIV infection. AIDS Patient Care STDs 1996;10:296-298.
31. Bowling A. What things are important in people's lives? A survey of the public's judgements to inform scales of health related quality of life. Soc Sci Med 1995;41:1447-1462.